MARINUS PHARMACEUTICALS, INC.: pre-tax income or loss from continuing operations

What this measure means

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Exact concept: us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• MARINUS PHARMACEUTICALS, INC.: total assets
• MARINUS PHARMACEUTICALS, INC.: total liabilities
• MARINUS PHARMACEUTICALS, INC.: stockholders equity
• MARINUS PHARMACEUTICALS, INC.: cash and cash equivalents
• MARINUS PHARMACEUTICALS, INC.: net income or loss
• MARINUS PHARMACEUTICALS, INC.: operating cash flow
• MARINUS PHARMACEUTICALS, INC.: revenue
• MARINUS PHARMACEUTICALS, INC.: financing cash flow
• MARINUS PHARMACEUTICALS, INC.: investing cash flow
• MARINUS PHARMACEUTICALS, INC.: retained earnings or deficit
• MARINUS PHARMACEUTICALS, INC.: basic weighted-average shares
• MARINUS PHARMACEUTICALS, INC.: diluted weighted-average shares
• MARINUS PHARMACEUTICALS, INC.: basic earnings per share
• MARINUS PHARMACEUTICALS, INC.: diluted earnings per share
• MARINUS PHARMACEUTICALS, INC.: net property, plant and equipment
• MARINUS PHARMACEUTICALS, INC.: share-based compensation expense
• MARINUS PHARMACEUTICALS, INC.: operating income or loss
• MARINUS PHARMACEUTICALS, INC.: current assets
• MARINUS PHARMACEUTICALS, INC.: interest expense
• MARINUS PHARMACEUTICALS, INC.: current liabilities
• MARINUS PHARMACEUTICALS, INC.: current accounts payable
• MARINUS PHARMACEUTICALS, INC.: net current accounts receivable
• MARINUS PHARMACEUTICALS, INC.: selling, general and administrative expense
• MARINUS PHARMACEUTICALS, INC.: research and development expense
• MARINUS PHARMACEUTICALS, INC.: common shares outstanding
• MARINUS PHARMACEUTICALS, INC.: cash including restricted cash
• MARINUS PHARMACEUTICALS, INC.: additional paid-in capital
• MARINUS PHARMACEUTICALS, INC.: accumulated other comprehensive income or loss
• MARINUS PHARMACEUTICALS, INC.: operating lease right-of-use asset
• MARINUS PHARMACEUTICALS, INC.: operating lease liability
• MARINUS PHARMACEUTICALS, INC.: long-term debt
• MARINUS PHARMACEUTICALS, INC.: gross property, plant and equipment
• MARINUS PHARMACEUTICALS, INC.: accumulated depreciation on property, plant and equipment
• MARINUS PHARMACEUTICALS, INC.: other noncurrent assets
• MARINUS PHARMACEUTICALS, INC.: accrued current liabilities
• MARINUS PHARMACEUTICALS, INC.: prepaid expenses and other current assets
• MARINUS PHARMACEUTICALS, INC.: profit or loss including noncontrolling interests
• MARINUS PHARMACEUTICALS, INC.: comprehensive income or loss
• MARINUS PHARMACEUTICALS, INC.: net income available to common stockholders
• MARINUS PHARMACEUTICALS, INC.: general and administrative expense
• MARINUS PHARMACEUTICALS, INC.: depreciation expense
• MARINUS PHARMACEUTICALS, INC.: depreciation, depletion and amortization
• MARINUS PHARMACEUTICALS, INC.: other nonoperating income or expense
• MARINUS PHARMACEUTICALS, INC.: interest paid, net

Inspect the source

Entity

MARINUS PHARMACEUTICALS, INC. / CIK 0001267813

Captured

2026-09-21T17:18:11.436Z

SEC response SHA-256

1a575eff225971488326996af5ff9f0c33a97740b77d0896b473d9302ab1dfdb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001267813.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))